N-Acetyl Cysteine and Delayed Onset of Thrombocytopenia

Doses used in studies

Safety in these studies

Overall tolerabilityReported
These findings suggest IV NAC may offer a preventive benefit against LAT in critically ill patients, though multicenter validation is needed to confirm generalizability across diverse clinical settings.
from: N-acetylcysteine reduces incidence and duration of linezolid-associated thrombocytopenia i

1 of 1 paper

N-acetylcysteine reduces incidence and duration of linezolid-associated thrombocytopenia in critically ill patients: A randomized controlled trial.